CN112203724A - 使用利格珠单抗治疗慢性自发性荨麻疹的方法 - Google Patents

使用利格珠单抗治疗慢性自发性荨麻疹的方法 Download PDF

Info

Publication number
CN112203724A
CN112203724A CN201980021766.9A CN201980021766A CN112203724A CN 112203724 A CN112203724 A CN 112203724A CN 201980021766 A CN201980021766 A CN 201980021766A CN 112203724 A CN112203724 A CN 112203724A
Authority
CN
China
Prior art keywords
dose
antibody
ige
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980021766.9A
Other languages
English (en)
Chinese (zh)
Inventor
T·塞韦林
P·洛
R·亚诺哈
S·科恩-沃斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN112203724A publication Critical patent/CN112203724A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201980021766.9A 2018-03-26 2019-03-25 使用利格珠单抗治疗慢性自发性荨麻疹的方法 Pending CN112203724A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647928P 2018-03-26 2018-03-26
US62/647,928 2018-03-26
US201962811800P 2019-02-28 2019-02-28
US62/811,800 2019-02-28
PCT/IB2019/052408 WO2019186369A1 (en) 2018-03-26 2019-03-25 Methods of treating chronic spontaneous urticaria using ligelizumab

Publications (1)

Publication Number Publication Date
CN112203724A true CN112203724A (zh) 2021-01-08

Family

ID=66476672

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980021766.9A Pending CN112203724A (zh) 2018-03-26 2019-03-25 使用利格珠单抗治疗慢性自发性荨麻疹的方法

Country Status (9)

Country Link
US (2) US20210115155A1 (https=)
EP (1) EP3773904A1 (https=)
JP (1) JP7589045B2 (https=)
KR (1) KR20200135826A (https=)
CN (1) CN112203724A (https=)
AU (1) AU2019244666A1 (https=)
CA (1) CA3094749A1 (https=)
IL (1) IL277474B2 (https=)
WO (1) WO2019186369A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250533A1 (en) * 2020-06-09 2021-12-16 Novartis Ag Methods of treatment using omalizumab or ligelizumab
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
CA3220757A1 (en) * 2021-06-14 2022-12-22 Novartis Ag Pharmaceutical formulation containing an anti-ige antibody
EP4384553A1 (en) * 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
CN1612751A (zh) * 2002-01-09 2005-05-04 诺瓦提斯公司 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗
AU2004315197A1 (en) * 2004-02-02 2005-08-18 Tanox, Inc. Identification of novel IgE epitopes
CN102993306A (zh) * 2003-02-01 2013-03-27 唐纳士公司 高亲和力抗人类IgE抗体
TW201343176A (zh) * 2012-04-16 2013-11-01 Novartis Ag 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
CN103764150A (zh) * 2011-06-29 2014-04-30 阿勒根公司 阿卡他定在治疗荨麻疹中的用途
CN104547325A (zh) * 2015-01-21 2015-04-29 李健 一种治疗慢性特发性荨麻疹的药物组合物及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1612751A (zh) * 2002-01-09 2005-05-04 诺瓦提斯公司 包括施用抗IgE抗体和抗过敏化合物、用于过敏性疾病的组合治疗
CN102993306A (zh) * 2003-02-01 2013-03-27 唐纳士公司 高亲和力抗人类IgE抗体
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
AU2004315197A1 (en) * 2004-02-02 2005-08-18 Tanox, Inc. Identification of novel IgE epitopes
CN103764150A (zh) * 2011-06-29 2014-04-30 阿勒根公司 阿卡他定在治疗荨麻疹中的用途
TW201343176A (zh) * 2012-04-16 2013-11-01 Novartis Ag 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
CN104547325A (zh) * 2015-01-21 2015-04-29 李健 一种治疗慢性特发性荨麻疹的药物组合物及其应用

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
NOARTIS: ""Clinical Trial Protocol [CQGE031 C2202 / NCT03437278] A multicenter, randomized, double-blind, placebo-controlled phase 2b dosefinding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous Urticaria (CSU)"", pages 19 - 20, Retrieved from the Internet <URL:https://clinicaltrials.gov/ProvidedOocs/78/NCT03437278/ ProCOOO.pdf> *
NOARTIS: ""Clinical Trial Protocol [CQGE031C2202/ NCT03437278] A multicenter, randomized, double-blind, placebo-controlled phase 2b dosefinding study to investigate the efficacy and safety of ligelizumab(QGE031) in adolescent patients with Chronic Spontaneous Urticaria(CSU)"", pages 19 - 20, Retrieved from the Internet <URL:https://clinicaltrials.gov/ProvidedOocs/78/NCT03437278/ ProCOOO.pdf> *
NOVARTIS: ""Oose-finding Study of OGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU"", Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/1\\ICT02477332> *
NOVARTIS: ""Study to Investigate the Efficacy and Safety of OGE031 in Adolescent Patients With Chronic Spontaneous Urticaria (CSU)"", Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/show/study/ |\\ICT03437278> *
RAGIP ERTAS: ""Anti IgE Therapy in Chronic Urticaria"", 《INTECH》, 31 May 2017 (2017-05-31), pages 109 *

Also Published As

Publication number Publication date
JP2021523881A (ja) 2021-09-09
JP7589045B2 (ja) 2024-11-25
US20210115155A1 (en) 2021-04-22
KR20200135826A (ko) 2020-12-03
EP3773904A1 (en) 2021-02-17
US20250026858A1 (en) 2025-01-23
WO2019186369A1 (en) 2019-10-03
RU2020134794A (ru) 2022-04-26
IL277474B1 (en) 2025-12-01
IL277474B2 (en) 2026-04-01
IL277474A (en) 2020-11-30
CA3094749A1 (en) 2019-10-03
RU2020134794A3 (https=) 2022-04-26
AU2019244666A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
JP7341996B2 (ja) Ｉｌ－１７アンタゴニストを用いて化膿性汗腺炎を治療すること
US20230303677A1 (en) Methods of treating new-onset plaque type psoriasis using il-17 antagonists
BR112013011176A2 (pt) métodos de tratamento de artrite reumatoide usando antagonistas de il-17
US20250026858A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
JP2019206535A (ja) Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
US20230235069A1 (en) Treatment of atopic dermatitis
IL291807A (en) Dosing regimens for treating or preventing c5-associated diseases
CA3062179A1 (en) Methods of selectively treating asthma using il-17 antagonists
RU2783540C2 (ru) Способы лечения хронической спонтанной крапивницы с применением лигелизумаба
WO2018158741A1 (en) Psoriasis disease modification following long-term treatment with an il-17 antagonist
US20220403018A1 (en) Methods of treating lichen planus using interleukin (il-17) antagonists
CN121443637A (zh) 用于治疗斑块状银屑病的方法和组合物
CN118488851A (zh) 特应性皮炎的治疗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210108